Novel Pathogen Associated Cancers (PQ12)

新型病原体相关癌症 (PQ12)

基本信息

  • 批准号:
    8550028
  • 负责人:
  • 金额:
    $ 73.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-24 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Nearly twenty percent of the world's cancer burden can be attributed to chronic infectious diseases. Most infection-associated cancers have been shown to have a viral etiology, though bacteria and parasites also contribute to the global cancer burden. All known virus-associated cancers are specifically increased among immunosuppressed individuals, and there are other cancers that likely have a viral etiology because they too are increased following immunosuppression. Lymphoma, anogenital malignancies and lung cancer have been found to be increasingly common in a diverse set of immunosuppressed individuals. We propose to identify a viral etiology of those cancers most likely attributable to infection in this application. Specifically, we will focus on the subset of lymphomas that are more common in immunosuppressed individuals but have not been consistently related to Epstein Barr Virus (Hodgkin lymphoma and diffuse large B-cell lymphoma), the nearly 50% of penile and vulvar cancers that have not been attributed to infection with human papillomavirus (HPV), and a wide variety of lung cancers in a young immunosuppressed population with limited exposure to tobacco. Our overall strategy will be to obtain samples from cancers that are significantly increased in multiple immunosuppressed populations, to perform high throughput sequencing of tumor transcriptomes and computational analyses to identify viral sequences, to develop assays to determine whether the viruses are generally associated with cancers using well documented case-control series, and to begin to investigate the mechanisms of viral carcinogenesis using Merkel Cell polyomavirus (MCPyV) as an example. We bring together a team of investigators with complementary expertise in cancer biology, infectious diseases, virus discovery, computational biology and epidemiology, which will have access to unique tumor specimens originating from individuals with HIV infection in Uganda as well as validation in HIV-negative Ugandans and transplant cohorts from the United States.
描述(由申请人提供):世界上近20%的癌症负担可归因于慢性传染病。大多数感染相关的癌症已被证明具有病毒病因,尽管细菌和寄生虫也有助于全球癌症负担。所有已知的病毒相关癌症在免疫抑制个体中特异性增加,并且还有其他可能具有病毒病因的癌症,因为它们也在免疫抑制后增加。淋巴瘤,肛门生殖器恶性肿瘤和肺癌已被发现是越来越常见的一组不同的免疫抑制个体。我们建议在本申请中鉴定最可能归因于感染的那些癌症的病毒病因。具体来说,我们将集中在淋巴瘤的子集,更常见于免疫抑制的个人,但并没有一贯相关的爱泼斯坦巴尔病毒(霍奇金淋巴瘤和弥漫性大B细胞淋巴瘤),近50%的阴茎和外阴癌没有归因于人乳头瘤病毒(HPV)感染,和多种肺癌在一个年轻的免疫抑制人群与烟草接触有限。我们的总体策略将是从在多种免疫抑制人群中显著增加的癌症中获得样本,对肿瘤转录组进行高通量测序和计算分析以鉴定病毒序列,开发检测方法以确定病毒是否通常与癌症相关,使用记录良好的病例对照系列,并以默克尔细胞多瘤病毒(MCPyV)为例,开始研究病毒致癌机制。我们汇集了一支在癌症生物学,传染病,病毒发现,计算生物学和流行病学方面具有互补专业知识的研究人员团队,他们将获得来自乌干达艾滋病毒感染者的独特肿瘤标本,以及来自美国的艾滋病毒阴性乌干达人和移植队列的验证。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Corey Casper其他文献

Corey Casper的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Corey Casper', 18)}}的其他基金

Scientific Core One
科学核心一
  • 批准号:
    10589643
  • 财政年份:
    2023
  • 资助金额:
    $ 73.64万
  • 项目类别:
HIV integration-mediated modulation of immune regulation in HPV-associated cancers
HIV 整合介导的 HPV 相关癌症免疫调节调节
  • 批准号:
    9982848
  • 财政年份:
    2016
  • 资助金额:
    $ 73.64万
  • 项目类别:
HIV integration-mediated modulation of immune regulation in HPV-associated cancers
HIV 整合介导的 HPV 相关癌症免疫调节调节
  • 批准号:
    9340125
  • 财政年份:
    2016
  • 资助金额:
    $ 73.64万
  • 项目类别:
HIV integration-mediated modulation of immune regulation in HPV-associated cancers
HIV 整合介导的 HPV 相关癌症免疫调节调节
  • 批准号:
    9129244
  • 财政年份:
    2016
  • 资助金额:
    $ 73.64万
  • 项目类别:
HIV integration-mediated modulation of immune regulation in HPV-associated cancers
HIV 整合介导的 HPV 相关癌症免疫调节调节
  • 批准号:
    9767057
  • 财政年份:
    2016
  • 资助金额:
    $ 73.64万
  • 项目类别:
Research Program: Global Oncology
研究项目:全球肿瘤学
  • 批准号:
    9001929
  • 财政年份:
    2015
  • 资助金额:
    $ 73.64万
  • 项目类别:
Research Program: Global Oncology
研究项目:全球肿瘤学
  • 批准号:
    8804796
  • 财政年份:
    2015
  • 资助金额:
    $ 73.64万
  • 项目类别:
Expanding independent research capacity in HIV-associated malignancies in Uganda
扩大乌干达艾滋病毒相关恶性肿瘤的独立研究能力
  • 批准号:
    8708481
  • 财政年份:
    2014
  • 资助金额:
    $ 73.64万
  • 项目类别:
Biologic Determinants of the Natural History of AIDS-Defining Cancers in Uganda
乌干达艾滋病定义癌症自然史的生物决定因素
  • 批准号:
    8929189
  • 财政年份:
    2014
  • 资助金额:
    $ 73.64万
  • 项目类别:
Biologic Determinants of the Natural History of AIDS-Defining Cancers in Uganda
乌干达艾滋病定义癌症自然史的生物决定因素
  • 批准号:
    8793997
  • 财政年份:
    2014
  • 资助金额:
    $ 73.64万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 73.64万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 73.64万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 73.64万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 73.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 73.64万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 73.64万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 73.64万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 73.64万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 73.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 73.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了